Clinical trials: Operable Esophageal Cancer, active
Gastric Cancer, Esophageal Cancer
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Anti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer…
- Conditions
- Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
- Trial name
- NCT03044613
- Testing
- Nivolumab, Relatlimab, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer
Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer
Perioperative chemotherapy (CHT) or CHT/RT combined with surgery is the standard therapeutic approach for the treatment of locally advanced cancer of the esophagus, gastroesophageal junction (GEJ), and stomach.
- Conditions
- Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, Gastric Cancer
- Trial name
- OESOFIT (NCT07671625)
- Testing
- Cardiorespiratory fitness (FsPS), Exercises you can do on your own at home, Enhanced Recovery After Surgery ERAS
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute